A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

A. Younes; J. M. Vose; A. D. Zelenetz; M. R. Smith; H. A. Burris; S. M. Ansell; J. Klein; W. Halpern; R. Miceli; E. Kumm; N. L. Fox; M. S. Czuczman

doi:10.1038/sj.bjc.6605987

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

A. Younes, J. M. Vose, A. D. Zelenetz, M. R. Smith, H. A. Burris, S. M. Ansell, J. Klein, W. Halpern, R. Miceli, E. Kumm, N. L. Fox, M. S. Czuczman

Hematology

Research output: Contribution to journal › Article › peer-review

107 Scopus citations

Abstract

Background: We conducted a multicentre Phase 1b/2 trial to evaluate the safety and efficacy of mapatumumab, a fully human agonistic monoclonal antibody to the tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with relapsed non-Hodgkin's lymphoma (NHL).Methods:Forty patients with relapsed or refractory NHL were treated with either 3 or 10 mg kg 1 mapatumumab every 21 days. In the absence of disease progression or prohibitive toxicity, patients received a maximum of six doses. Results: Mapatumumab was well tolerated, with no patients experiencing drug-related hepatic or other dose-limiting toxicity. Three patients with follicular lymphoma (FL) experienced clinical responses, including two with a complete response and one with a partial response. Immunohistochemistry staining of the TRAIL-R1 suggested that strong staining in tumour specimens did not appear to be a requirement for mapatumumab activity in FL. Conclusions: Mapatumumab is safe and has promising clinical activity in patients with FL.

Original language	English (US)
Pages (from-to)	1783-1787
Number of pages	5
Journal	British journal of cancer
Volume	103
Issue number	12
DOIs	https://doi.org/10.1038/sj.bjc.6605987
State	Published - Dec 7 2010

Keywords

Apo2L
TRAIL
apoptosis

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/sj.bjc.6605987

Cite this

@article{82bf528bbba14511aa620bbfd717beb4,

title = "A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma",

abstract = "Background: We conducted a multicentre Phase 1b/2 trial to evaluate the safety and efficacy of mapatumumab, a fully human agonistic monoclonal antibody to the tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with relapsed non-Hodgkin's lymphoma (NHL).Methods:Forty patients with relapsed or refractory NHL were treated with either 3 or 10 mg kg 1 mapatumumab every 21 days. In the absence of disease progression or prohibitive toxicity, patients received a maximum of six doses. Results: Mapatumumab was well tolerated, with no patients experiencing drug-related hepatic or other dose-limiting toxicity. Three patients with follicular lymphoma (FL) experienced clinical responses, including two with a complete response and one with a partial response. Immunohistochemistry staining of the TRAIL-R1 suggested that strong staining in tumour specimens did not appear to be a requirement for mapatumumab activity in FL. Conclusions: Mapatumumab is safe and has promising clinical activity in patients with FL.",

keywords = "Apo2L, TRAIL, apoptosis",

author = "A. Younes and Vose, {J. M.} and Zelenetz, {A. D.} and Smith, {M. R.} and Burris, {H. A.} and Ansell, {S. M.} and J. Klein and W. Halpern and R. Miceli and E. Kumm and Fox, {N. L.} and Czuczman, {M. S.}",

note = "Funding Information: We thank Larry Lo for developing and running the pharmacokinetic and immunogenicity assays. This study was supported by Human Genome Sciences, Inc. Mapatumumab results in relapsed/refractory NHL. Clinical Observation, Interventions, and Therapeutic Trials.",

year = "2010",

month = dec,

day = "7",

doi = "10.1038/sj.bjc.6605987",

language = "English (US)",

volume = "103",

pages = "1783--1787",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

AU - Younes, A.

AU - Vose, J. M.

AU - Zelenetz, A. D.

AU - Smith, M. R.

AU - Burris, H. A.

AU - Ansell, S. M.

AU - Klein, J.

AU - Halpern, W.

AU - Miceli, R.

AU - Kumm, E.

AU - Fox, N. L.

AU - Czuczman, M. S.

N1 - Funding Information: We thank Larry Lo for developing and running the pharmacokinetic and immunogenicity assays. This study was supported by Human Genome Sciences, Inc. Mapatumumab results in relapsed/refractory NHL. Clinical Observation, Interventions, and Therapeutic Trials.

PY - 2010/12/7

Y1 - 2010/12/7

N2 - Background: We conducted a multicentre Phase 1b/2 trial to evaluate the safety and efficacy of mapatumumab, a fully human agonistic monoclonal antibody to the tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with relapsed non-Hodgkin's lymphoma (NHL).Methods:Forty patients with relapsed or refractory NHL were treated with either 3 or 10 mg kg 1 mapatumumab every 21 days. In the absence of disease progression or prohibitive toxicity, patients received a maximum of six doses. Results: Mapatumumab was well tolerated, with no patients experiencing drug-related hepatic or other dose-limiting toxicity. Three patients with follicular lymphoma (FL) experienced clinical responses, including two with a complete response and one with a partial response. Immunohistochemistry staining of the TRAIL-R1 suggested that strong staining in tumour specimens did not appear to be a requirement for mapatumumab activity in FL. Conclusions: Mapatumumab is safe and has promising clinical activity in patients with FL.

AB - Background: We conducted a multicentre Phase 1b/2 trial to evaluate the safety and efficacy of mapatumumab, a fully human agonistic monoclonal antibody to the tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with relapsed non-Hodgkin's lymphoma (NHL).Methods:Forty patients with relapsed or refractory NHL were treated with either 3 or 10 mg kg 1 mapatumumab every 21 days. In the absence of disease progression or prohibitive toxicity, patients received a maximum of six doses. Results: Mapatumumab was well tolerated, with no patients experiencing drug-related hepatic or other dose-limiting toxicity. Three patients with follicular lymphoma (FL) experienced clinical responses, including two with a complete response and one with a partial response. Immunohistochemistry staining of the TRAIL-R1 suggested that strong staining in tumour specimens did not appear to be a requirement for mapatumumab activity in FL. Conclusions: Mapatumumab is safe and has promising clinical activity in patients with FL.

KW - Apo2L

KW - TRAIL

KW - apoptosis

UR - http://www.scopus.com/inward/record.url?scp=78650021203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650021203&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6605987

DO - 10.1038/sj.bjc.6605987

M3 - Article

C2 - 21081929

AN - SCOPUS:78650021203

SN - 0007-0920

VL - 103

SP - 1783

EP - 1787

JO - British journal of cancer

JF - British journal of cancer

IS - 12

ER -

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this